Loading...
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
Hiller, L Dunn, J Loi, S Vallier, A Howe, D Cameron, D Miles, D Wardley, Andrew M Earl, H
Hiller, L
Dunn, J
Loi, S
Vallier, A
Howe, D
Cameron, D
Miles, D
Wardley, Andrew M
Earl, H
Citations
Altmetric:
Abstract
Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In this trial there will be a trade-off between a possible small decrease in disease-free survival (DFS) with 6-months and reduced cardiotoxicity and cost.
Description
Date
2018-04-05
Publisher
Collections
Files
Keywords
Type
Article
Citation
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. 2018, 18(1): 391 BMC Cancer